Huttig Bldg Products (HBP) 4.40 $HBP
Huttig Building Products, Inc. [HBP] to Ring The NASDAQ Stock Market Opening Bell
GlobeNewswire - Fri Apr 25, 9:42AM CDT
What:
Huttig Building Products, Inc. Announces First Quarter 2014 Results
Marketwire - Thu Apr 24, 5:01AM CDT
Huttig Building Products, Inc. (Huttig, or the Company) (NASDAQ: HBP), a leading domestic distributor of millwork, building materials and wood products, today reported financial results for the first quarter ended March 31, 2014.
Helix BioPharma Corp. Receives U.S. Food and Drug Administration Approval to Initiate a Clinical Trial of L-DOS47 in Combination With Pemetrexed and Carboplatin
Marketwire - Tue Apr 22, 7:31AM CDT
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced that it has received approval from the U.S. Food and Drug Administration ("FDA"
, to initiate a Phase I clinical trial with L-DOS47.
Helix BioPharma Corp. Initiates Enrollment for Eighth Cohort in Polish Phase I/II Clinical Study of Its Lung Cancer Drug Candidate L-DOS47
Marketwire Canada - Mon Apr 07, 3:31PM CDT
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced the opening of patient screening for the eighth dose level cohort in its ongoing Phase I/II clinical safety, tolerability and preliminary efficacy study of L-DOS47 in Poland. This follows completion of the first treatment cycle in the three patients enrolled in the seventh dose level cohort, in which L-DOS47 therapy was well tolerated as reviewed by the Trial Steering Committee.
Helix BioPharma Corp. Submits L-DOS47 Investigational New Drug Application With U.S. Food and Drug Administration
Marketwire Canada - Thu Apr 03, 4:18PM CDT
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced the recent submission of an Investigational New Drug ("IND" application with the U.S. Food and Drug Administration ("FDA" for approval to initiate a Phase I clinical trial with L-DOS47. The study is entitled "A Phase I, Open Label, Dose Escalation Study of Immunoconjugate L-DOS47 in Combination with Standard Doublet Therapy of Pemetrexed/Carboplatin in Patients with Stage IV (TNM M1a and M1b) Recurrent or Metastatic Non-Squamous Non-Small Cell Lung Cancer ("NSCLC".
MoistureShield Composite Decking Expands Distribution Network with 12 New Distribution Locations
PRWeb - Thu Mar 20, 2:14AM CDT
MoistureShield composite decking has expanded its 2014 distributor network in the U.S. Sunbelt and West Coast regions with recent additions of: Huttig Building Products in Phoenix, Ariz.; Nashville, Tenn.; and Jackson, Miss. BlueLinx in Tampa, Miami and Jacksonville, Fla. Dixie Plywood and Lumber Company in San Antonio, Houston and Dallas, Texas Universal Forest Products in Thornton and Riverside, Calif. Intermountain Supply in Spokane, Wash.
Helix BioPharma Corp. Announces Fiscal Q2 2014 Results
Marketwire Canada - Fri Mar 14, 4:01PM CDT
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today announced financial results for the three and six-month periods ended January 31, 2014 and 2013.
Helix BioPharma Corp. Announces Appointment of New Director and Observer to the Board of Directors
Marketwire Canada - Tue Mar 11, 4:00PM CDT
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today announced the appointment of Mr. Sylwester Cacek to the board of directors. Mr. Cacek's appointment was effective March 7, 2014.
Huttig Building Products, Inc. Announces Fourth Quarter and Full Year 2013 Results
Marketwire - Thu Feb 20, 1:00AM CST
Huttig Building Products, Inc. (Huttig, or the Company) (NASDAQ: HBP), a leading domestic distributor of millwork, building materials and wood products, today reported financial results for the fourth quarter and year ended December 31, 2013.
Huttig Building Products, Inc. [HBP] to Ring The NASDAQ Stock Market Opening Bell
GlobeNewswire - Fri Apr 25, 9:42AM CDT
What:
Huttig Building Products, Inc. Announces First Quarter 2014 Results
Marketwire - Thu Apr 24, 5:01AM CDT
Huttig Building Products, Inc. (Huttig, or the Company) (NASDAQ: HBP), a leading domestic distributor of millwork, building materials and wood products, today reported financial results for the first quarter ended March 31, 2014.
Helix BioPharma Corp. Receives U.S. Food and Drug Administration Approval to Initiate a Clinical Trial of L-DOS47 in Combination With Pemetrexed and Carboplatin
Marketwire - Tue Apr 22, 7:31AM CDT
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced that it has received approval from the U.S. Food and Drug Administration ("FDA"
, to initiate a Phase I clinical trial with L-DOS47. Helix BioPharma Corp. Initiates Enrollment for Eighth Cohort in Polish Phase I/II Clinical Study of Its Lung Cancer Drug Candidate L-DOS47
Marketwire Canada - Mon Apr 07, 3:31PM CDT
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced the opening of patient screening for the eighth dose level cohort in its ongoing Phase I/II clinical safety, tolerability and preliminary efficacy study of L-DOS47 in Poland. This follows completion of the first treatment cycle in the three patients enrolled in the seventh dose level cohort, in which L-DOS47 therapy was well tolerated as reviewed by the Trial Steering Committee.
Helix BioPharma Corp. Submits L-DOS47 Investigational New Drug Application With U.S. Food and Drug Administration
Marketwire Canada - Thu Apr 03, 4:18PM CDT
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced the recent submission of an Investigational New Drug ("IND"
application with the U.S. Food and Drug Administration ("FDA" for approval to initiate a Phase I clinical trial with L-DOS47. The study is entitled "A Phase I, Open Label, Dose Escalation Study of Immunoconjugate L-DOS47 in Combination with Standard Doublet Therapy of Pemetrexed/Carboplatin in Patients with Stage IV (TNM M1a and M1b) Recurrent or Metastatic Non-Squamous Non-Small Cell Lung Cancer ("NSCLC". MoistureShield Composite Decking Expands Distribution Network with 12 New Distribution Locations
PRWeb - Thu Mar 20, 2:14AM CDT
MoistureShield composite decking has expanded its 2014 distributor network in the U.S. Sunbelt and West Coast regions with recent additions of: Huttig Building Products in Phoenix, Ariz.; Nashville, Tenn.; and Jackson, Miss. BlueLinx in Tampa, Miami and Jacksonville, Fla. Dixie Plywood and Lumber Company in San Antonio, Houston and Dallas, Texas Universal Forest Products in Thornton and Riverside, Calif. Intermountain Supply in Spokane, Wash.
Helix BioPharma Corp. Announces Fiscal Q2 2014 Results
Marketwire Canada - Fri Mar 14, 4:01PM CDT
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today announced financial results for the three and six-month periods ended January 31, 2014 and 2013.
Helix BioPharma Corp. Announces Appointment of New Director and Observer to the Board of Directors
Marketwire Canada - Tue Mar 11, 4:00PM CDT
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today announced the appointment of Mr. Sylwester Cacek to the board of directors. Mr. Cacek's appointment was effective March 7, 2014.
Huttig Building Products, Inc. Announces Fourth Quarter and Full Year 2013 Results
Marketwire - Thu Feb 20, 1:00AM CST
Huttig Building Products, Inc. (Huttig, or the Company) (NASDAQ: HBP), a leading domestic distributor of millwork, building materials and wood products, today reported financial results for the fourth quarter and year ended December 31, 2013.
